Group 1 - The Schall Law Firm is investigating claims on behalf of investors of BellRing Brands, Inc. for potential violations of securities laws [1] - The investigation centers on whether BellRing made false or misleading statements and failed to disclose important information to investors [2] - During its Q2 earnings call on May 6, 2026, BellRing announced that Q3 sales growth would slow to "low-single-digits" due to customers optimizing inventories, leading to a nearly 19% drop in shares on the same day [2]

Group 1 - The Schall Law Firm is investigating claims on behalf of investors of Laser Photonics Corporation for potential violations of securities laws [1] - The investigation centers on whether Laser Photonics issued false or misleading statements and failed to disclose important information to investors [2] - Laser Photonics received a notice from Nasdaq regarding its non-compliance with listing rules due to delinquent filings, leading to a more than 6.5% drop in its share price [2]

LOS ANGELES, July 16, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of KBR, Inc. ("KBR" or "the Company") (NYSE: KBR) for violations of the securities laws. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: The Schall Law Firm Brian Schall, Esq. 310-301-3335 [email protected] www.schallfirm.com The investigation focus ...

Core Viewpoint - The Schall Law Firm is investigating Centene Corporation for potential violations of securities laws, particularly regarding misleading statements and undisclosed information that may have affected investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Centene issued false or misleading statements and failed to disclose critical information to investors [2]. - A Seeking Alpha report indicated that Centene's shares declined after the company withdrew its 2025 earnings guidance, citing higher-than-expected costs related to Medicaid enrollees and underperformance in its Affordable Care Act plans [2]. - Following the announcement, Centene's shares fell by more than 39.5% during intraday trading on the same day [2]. Group 2: Company Background - Centene Corporation is involved in providing healthcare services, particularly through Medicaid and Affordable Care Act plans [2]. - The company reported a significant increase in medical cost trends in areas such as behavioral health, home health, and high-cost drugs [2].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of PepGen Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its lead product candidate, PGN-EDO51, and its clinical study, CONNECT2 [1][2]. Allegations - The lawsuit claims that during the class period from March 7, 2024, to March 3, 2025, PepGen misrepresented the effectiveness and safety of PGN-EDO51 [1]. - It is alleged that the CONNECT2 study was dangerous or deficient for FDA approval, leading to the likelihood of halting the study [1]. - The complaint states that the clinical, regulatory, and commercial prospects of PGN-EDO51 were overstated, making the company's public statements materially false and misleading [1]. Class Action Details - Shareholders who purchased shares of PepGen during the specified class period are encouraged to register for the class action by August 8, 2025 [2]. - Registration allows shareholders to receive updates on the case and does not incur any costs or obligations [2]. Law Firm Background - The Gross Law Firm is recognized for its commitment to protecting investors' rights against deceit and fraud, aiming to hold companies accountable for misleading practices [3].

Core Viewpoint - Berger Montague is investigating potential securities law violations involving Petco Health and Wellness Company, Inc., following a class action lawsuit filed on behalf of investors who acquired Petco securities between January 14, 2021, and June 5, 2025 [1][2] Company Overview - Petco, headquartered in San Diego, CA, focuses on enhancing the lives of pets and pet parents [2] Allegations and Financial Impact - The complaint alleges that Petco made materially false and misleading statements regarding its pandemic-related tailwinds and the sustainability of its premium pet food business model [3] - It is claimed that the company overstated its ability to deliver profitable growth while downplaying operational challenges, leading to significant declines in Petco's stock price [3] - Notably, Petco's stock price dropped by more than 20% on August 24, 2023, following a downward revision of financial guidance, with further declines after subsequent disclosures and leadership changes [3]

Core Scientific and CoreWeave Acquisition - Rowley Law PLLC is investigating potential securities law violations by Core Scientific and its board of directors regarding the proposed acquisition by CoreWeave [1] - The acquisition involves stockholders receiving 0.1235 shares of CoreWeave common stock for each share of Core Scientific stock held [1] - The transaction is valued at approximately $9 billion and is expected to close in the fourth quarter of 2025 [1]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to alleged misleading statements and concealment of material facts related to the company's capital allocation and dividend strategy [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that Organon & Co. provided overly positive statements to investors while concealing significant adverse facts about its priorities, particularly regarding capital allocation and a debt reduction strategy following the acquisition of Dermavant [3]. - The company's regular quarterly dividend was reduced by 70%, which was not disclosed to investors prior to the announcement [3]. Stock Price Impact - Following the announcement of the dividend cut, Organon's stock price plummeted from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [3]. Class Action Details - The class period for the lawsuit is defined as October 31, 2024, to April 30, 2025 [3]. - Shareholders are encouraged to register for the class action by July 22, 2025, to potentially be appointed as lead plaintiffs [4]. Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies engage in responsible business practices, seeking recovery for losses incurred due to misleading statements or omissions [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of West Pharmaceutical Services, Inc. regarding a class action lawsuit due to alleged misleading statements and operational inefficiencies that impacted the company's financial performance during the specified class period [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from February 16, 2023, to February 12, 2025 [3]. - Allegations include: - The company claimed strong visibility into customer demand while actually facing significant destocking in its high-margin HVP portfolio [3]. - The SmartDose device, marketed as a high-margin growth product, was found to be dilutive to profit margins due to operational inefficiencies [3]. - Margin pressures raised the risk of costly restructuring activities, including exiting continuous glucose monitoring contracts with long-term customers [3]. - Positive statements made by the defendants regarding the company's business and prospects were materially false or misleading [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by the deadline of July 7, 2025, to participate in the case without any cost or obligation [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [5]. - The firm seeks recovery for investors who suffered losses due to false or misleading statements that led to artificial inflation of the company's stock [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Vestis Corporation regarding a class action lawsuit due to allegations of misleading statements and failure to meet growth expectations, leading to a significant drop in stock price [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that Vestis Corporation provided overly positive statements while concealing material adverse facts about its business growth capabilities, particularly its inability to execute strategic initiatives aimed at improving customer experience and retention [3]. Financial Performance - On May 7, 2025, Vestis announced disappointing financial results for Q2 of fiscal 2025, withdrew its revenue and growth guidance for the full fiscal year, and provided third-quarter guidance that was significantly below market expectations. The company cited "lost business in excess of new business" and "lower adds over stops" as reasons for its poor performance [3]. Stock Price Impact - Following the announcement of poor financial results, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in just one day [3]. Class Action Details - Shareholders who purchased shares of Vestis during the class period from May 2, 2024, to May 6, 2025, are encouraged to register for the class action lawsuit, with a deadline for lead plaintiff appointment set for August 8, 2025 [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and seeks recovery for those who suffered losses due to misleading statements or omissions by companies, emphasizing the importance of responsible business practices [5].